Introduction
============

Preterm birth is the leading cause of death and neurodevelopmental related disability in early life ([@B47]). In resource rich nations such as Australia, the incidence of moderate-late preterm birth specifically now accounts for ∼80% of all preterm births ([@B19]; [@B41]). These neonates have a high survival rate and a low incidence of gross neuroanatomical damage on routine clinical imaging; however, there is increasing evidence of microcystic white matter injury when assessed using MRI. Even amongst those infants who appear well at the time of hospital discharge, and are free of gross neuroanatomical lesions, there remains a high burden of later cognitive difficulties and neurodevelopmental disorders such as anxiety and attention deficit hyperactivity disorder (ADHD) ([@B1]; [@B21]; [@B102]; [@B114]; [@B83]; [@B7]; [@B19]; [@B116]). The long-term individual, familial and socio-economic burden of these issues remains profound; with rates of preterm birth at around 10%, and with increasing numbers of children surviving, there is an urgent need to develop novel therapeutic options to mitigate, or prevent, the ongoing neurological burden of preterm birth.

Myelination of white matter tracts continues throughout late gestation and following birth in areas such as the hippocampus and cerebellum: reduction in brain volumes and functionality of these regions are evident in children that were born preterm ([@B125]; [@B121]; [@B120]; [@B157]). In particular myelination by mature oligodendrocytes is ongoing throughout this late gestation stage and is vulnerable to insults and excitotoxic damage associated with early exposure to the *ex utero* environment ([@B4]; [@B5]; [@B92]). *In utero*, the fetal neurosteroid allopregnanolone is responsible for protection from neurological insults, modulating fetal behavior leading to the onset of a 'sleep-like state,' and promoting myelination through its action on the inhibitory GABA~A~ receptors of the central nervous system (CNS) ([@B105]; [@B103]; [@B54]). Importantly, recent studies suggest that behavioral and cognitive outcomes are tightly linked with gestational age ([@B12]). Any decrement in gestation, even across 'early term' (37/38 weeks' gestation) is associated with, on a population basis, impaired cognitive and developmental outcomes compared to outcomes found in children born at full term (39--40 weeks gestational age) ([@B12]).

Birth is necessarily associated with the loss of the fetus from the placenta-maternal unit, and therefore separation from any trophic factors derived from either mother or placenta. Preterm birth results in the premature loss of placentally supplied allopregnanolone during a period when it is critical for optimal neurodevelopment ([@B67]). Whilst neurosteroid therapy has been evaluated for the treatment of traumatic brain injury (TBI) and epilepsy ([@B108]; [@B162]; [@B163]; [@B119]), therapeutic use of neurosteroids following preterm birth requires further evaluation.

Neurological Outcomes of Preterm Birth
======================================

Despite only comprising 10% of births, preterm birth is the leading cause of death and neurodevelopmental related disability in neonates, accounting for up to 50% of neonatal deaths ([@B137]). Furthermore, the ongoing morbidity risks of preterm birth remain unacceptably high with up to 50% of survivors developing some form of long-term neurodevelopmental disability ([@B91]; [@B1]). Cerebral white matter injury in the preterm infant varies based on gestational age at the time of birth. Historically, injury following early preterm birth was characterized by intraventricular hemorrhage and, or, periventricular leukomalacia (PVL) ([@B155], [@B154]). In survivors of early preterm birth weighing \<1,500 g approximately 10% develop cerebral palsy as a result of these gross insults and necrosis ([@B156]). However, with improvements in perinatal care these gross structural lesions are now far less common, whereas diffuse white matter injury (DWMI) demonstrable on MRI, but not routine screening cranial ultrasound, is increasingly recognized as the key contributor to the pathophysiology of preterm-associated brain injury. It is now established that impaired cognition, sensory and psychological functioning in children born preterm is associated with DWMI ([@B149]). Furthermore, DWMI is a recognized risk factor for the development of neurobehavioral disorders such as autism-spectrum disorders and ADHD ([@B149]). The underlying pathophysiological mechanisms of DWMI are poorly understood but are suggested to be due to immature oligodendrocyte arrest resulting in impaired myelination.

In infants that were born \<32 weeks' gestation, it has recently been shown that reductions in white matter volume in areas such as the fornix and the cingulum observed by MRI at the time of birth remained present until 19 years of age and were associated with impairments in memory functions ([@B15]). The Stockholm Neonatal Project has also recently published the results of a longitudinal trial following infants born \<36 weeks' gestation up until 18 years of age when they undertook psychological assessment including general intelligence and executive functioning measures. Significantly poorer outcomes were observed for preterm children in areas such as IQ, attention, working memory, and cognitive flexibility ([@B153]). Most importantly, however, is that the executive functioning deficits did not correlate with reductions in white matter or gray matter volumes evident by MRI following birth, but the microstructure of white matter tracts was altered at adolescence. Thus, this study found that following preterm birth, and in the absence of obvious perinatal brain injury, the alterations observed in white matter microstructure during adolescence correlate with executive function and general cognitive abilities. Furthermore, it suggested that disruption to neural pathways, as opposed to reductions in brain volume, is involved in the impairment of neurodevelopment following preterm birth. In addition to established preterm birth related disorders, such as cerebral palsy, there is now a growing body of evidence suggesting that preterm infants from moderate-late preterm pregnancies are much more likely to develop neurodevelopmental morbidities and learning disorders that become apparent at school age, with anxiety and ADHD being the most commonly diagnosed ([@B82]; [@B21]; [@B102]; [@B114]; [@B81]; [@B83]; [@B7]; [@B19]; [@B116]; [@B12]).

Attention deficit hyperactivity disorder is characterized by a deficit in behavioral inhibition, inattention, impulsivity and social difficulties, and in a Norwegian cohort of preterm/low birth weight children at 5 years old was more commonly diagnosed in males ([@B39]). In the same cohort, the females were more likely to be diagnosed with anxiety ([@B39]) highlighting that the behavioral outcomes of preterm birth occur in a sex-dependent manner. In a large Danish cohort children born at 34--36 weeks' gestation (moderate-late preterm range) had an 80% increased risk of being diagnosed with ADHD compared to children born after 37 weeks' gestation, a larger percentage of these were also male ([@B82]). Furthermore, in a Swedish cohort, the amount of ADHD medication purchased for ex-premature school-aged males was more than three times as much than for females, and the amount purchased increased by degree of immaturity at birth ([@B81]). In addition to anxiety and ADHD, incidences of autism and depression are also increased following preterm birth. Children in the United States that were born moderate-late preterm have been reported to have twice the incidence of autism at 10 years of age ([@B129]). Parent-reported mental health rates in the United States are also higher for ex-preterm children than the general population for children and adolescents, with a prevalence of 22.9% compared to 15.5% in the general pediatric population ([@B138]). This study also revealed that ex-preterm children have 61% higher risk of having serious emotional/behavioral problems; specifically, a 33% higher chance of developing depression and a 58% higher chance of developing anxiety in childhood and adolescence ([@B138]).

School-related problems also arise in children following preterm birth, with those born preterm needing more special educational support, having an increased risk of repeating a grade and lower overall reading and mathematics scores compared to children born at full term ([@B21]). These findings appear to be consistent internationally with numerous cohort studies observing that moderate-late ex-premature children have a 1.3- to 2.8-fold increased risk for requiring special education, and a 1.3- to 2.2-fold increased risk of repeating grades at ages 5--10 ([@B59]; [@B101]; [@B148]; [@B48]). Furthermore, another study identified reading, writing, and spelling difficulties in 9- to 11-year-old ex-premature children compared to those born full term ([@B71]). Even at just 3--4 years of age impairments to visuospatial processing, spatial working memory, and sustained attention have been documented following preterm birth where major neurological deficits were not present at the time of birth ([@B151]).

The direct impact of preterm birth on cognitive function is hard to quantify as it is confounded by many of the complex socio-economic, environmental and other factors that precipitated preterm birth in the first place. Additionally, given the plasticity of the developing brain, the timing of cognitive assessment needs to recognize the prognostic limitations of early assessment, especially for those born at extremes of gestational age. Studies comparing cognitive delays in toddlers at 2 years of age do not find any significant difference between preterm and term when corrected for prematurity ([@B18]; [@B34]; [@B126]; [@B161]). Alternatively, studies based in Swedish, American, and French cohorts found that 5- to 10-year old ex-premature children are twice as likely to score \<85 on an IQ (intelligence quotient) test than term born children and that this is correlated with the gestational age at birth, with those being born more preterm at the highest risk of severe cognitive impairments ([@B130]; [@B89]; [@B147]). However, a much larger and comprehensive longitudinal American study in late-preterm ex-preterm 4- to 15-year olds found no significant differences in IQ based on 11 different cognitive tests at every age group ([@B48]). These results suggest that intellectual disability may not be as prevalent following late-preterm birth as other negative outcomes such as behavioral disorders and poor school performance, suggesting that poor school performance may reflect behavioral disruptions that impact ability to pay attention and learn during class, rather than a result of reduced cognitive capacity.

Exposure to the *ex utero* Environment and Associated Damage
============================================================

Preterm birth abruptly removes the newborn from the supportive *in utero* environment experienced by a fetus of the same post-conceptional age. Organ maturation and function throughout the body changes tempo dramatically in response to this premature separation from the maternoplacental unit. Brain development requires neurotrophic and gliotrophic support during this time and so is vulnerable following preterm birth as it loses placental steroid support, the supply of precursors for fetal neurosteroid production, and other placentally supplied nutrients. In addition, premature loss of these steroids exposes the developing brain to increased stimulation and excitotoxic damage. Damage to oligodendrocytes of the developing nervous system can occur during this vulnerable developmental window prior to term gestation.

The oligodendrocyte development lineage is sensitive to premature exposure to the external environment, leading to injury by chemical and mechanical damage. This involves increased levels of reactive oxygen species following the rise in excitation after preterm birth and early exposure to the *ex utero* environment ([@B2]; [@B13]). Demyelinated regions in relapsing remitting multiple sclerosis undergo remyelination but residual impaired motor coordination may remain ([@B38]). Similarly, after preterm birth myelination continues and animal studies have shown less marked deficits at the equivalent of childhood, compared to the reduced myelination seen at term equivalent age. Despite this 'catch up' *ex utero* myelination, these children experience impaired learning ability and motor coordination, suggesting a similar causal pathway ([@B121]). Furthermore, reductions in myelination are apparent in a rat model of ADHD ([@B80]), and decreases in the white matter volumes of vulnerable regions such as the hippocampus and cerebellum are evident on magnetic resonance imaging (MRI) comparing term and preterm neonates ([@B26]).

Treatment Options for Preventing Poor Neurological Outcomes
===========================================================

In an effort to ameliorate or prevent preterm-associated brain damage a number of therapies have been adopted. However, despite the increasing body of evidence highlighting the increased neurodevelopmental vulnerability at all gestational ages below full term (39--40 weeks' gestation) no targeted therapies are available in the perinatal period to those infants born late preterm (34--36 weeks). For the less mature infants, maternal magnesium sulfate has been shown to reduce cerebral palsy in extreme preterm neonates, but the number needed to treat remains high, highlighting the need for other therapeutic approaches. A Cochrane systematic review of five large trials comprising 6,145 babies found that the incidence of cerebral palsy in preterm neonates dropped from 5 to 3.4% following antenatal magnesium sulfate therapy ([@B37]). A recent study where magnesium sulfate was given between 6 days and 12 h before unilateral hypoxic ischemia in neonatal rats identified that maximal neuronal protection was achieved by treatment only 24 h before the insult ([@B72]), which may be sufficient in some instances of preterm birth. Although promising, a limitation of this therapy is the need for antenatal rather than postnatal treatment, especially considering that more than 50% of preterm births are spontaneous and thus antenatal therapy cannot be initiated with appropriate timing. Human and animal studies have demonstrated a lack of neurological improvement following postnatal magnesium sulfate therapy in the context of chorioamnionitis induced preterm birth and asphyxia associated with preterm labor ([@B62]; [@B43]), thus although magnesium sulfate offers some therapeutic benefit, it is not, in itself sufficient to reduce preterm-related morbidity and rather may be suitable as an adjunct therapy.

The antioxidant melatonin has also been investigated for its neuroprotective benefits in animal models due to its roles in modulating neuroinflammation and reducing reactive oxygen species ([@B23]). In neonatal stroke and hemorrhage rat models pre-treatment with melatonin reduced the neuroinflammation and damage associated with stroke, whilst post-treatment reduced the amount of tissue death and improved cognitive and sensorimotor outcomes ([@B78]; [@B152]). However, despite entering clinical trials there are few conclusive results available, with a Cochrane systematic review finding no randomized trials published as yet ([@B159]). Therefore, the long-term benefit of this treatment for neurobehavioral outcomes awaits the result of further randomized control trials.

Controlled therapeutic hypothermia in late preterm and term infants with hypoxic ischaemic encephalopathy has demonstrated well-established benefits, such as reduced mortality and decreased long-term neurodevelopmental disability, if implemented within 6 h of the insult occurring ([@B60]; [@B75]). The physiological instability and vulnerability of the preterm infant means that therapeutic hypothermia is unlikely to be an appropriate intervention in this cohort. Even a small decrement in gestational age (to 34--35 week GA infants with HIE) at initiation of hypothermia was associated with an increase in over-cooling ([@B75]) and other hypothermia-associated complications in 90% of the preterm group versus 81.3% in the term cohort ([@B117]). In this small retrospective cohort study, 66.7% of the preterm neonates that received hypothermia therapy had evidence of white matter injury, whilst just 25% of the term neonates with HIE showed signs of white matter injury following an asphyxial insult managed with therapeutic hypothermia. These results are difficult to interpret, however, due to the lack of a normothermic preterm-control group. Importantly, all deaths following the hypothermia therapy were in the preterm group, highlighting their increased vulnerability compared to the term neonates. Similarly, a small retrospective cohort analysis between 2007 and 2015 of preterm infants 33--35 weeks' gestation who received whole body hypothermia revealed that 50% experienced mortality or moderate to severe neurodevelopmental impairment as a result of the therapy ([@B55]). Currently there is an ongoing clinical trial implementing whole-body cooling in American preterm neonates born at 33--35 GA with moderate to severe neonatal encephalopathy, but as it is still in the recruiting stage results are not yet available (*[ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT01793129*). The American Academy of Pediatrics committee advises that hypothermia should not be undertaken on preterm neonates due to the associated risks, unless it is performed in a research setting ([@B24]). These findings suggest that hypothermia may limit key developmental processes in the immediate postnatal period and this may limit its use in all but late preterm neonates, pending the outcome of the current clinical trial. Thus, the development of further adjunct therapy seems essential to improving neurodevelopmental outcome in the preterm infant.

Placental Contribution to *in utero* Brain Development
======================================================

The placenta plays an essential role in ensuring fetal neurodevelopment occurs correctly by secreting growth regulating factors including neurosteroid hormones throughout pregnancy ([Figure 1](#F1){ref-type="fig"}). Neurosteroids are endogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors. In late gestation, the fetus is maintained in a 'sleep-like' state, characterized by low levels of arousal-like activity. This ensures that excitation of the brain is limited, engendering a level of protection from excessive excitation and ultimately allowing sufficient energy for demanding developmental processes such as myelination to occur ([@B105]; [@B103]). This fetal 'sleep' state is maintained by an elevated level of the neurosteroid allopregnanolone, and decreasing the synthesis of this neurosteroid has been shown to increase the excitation of the brain, potentially disrupting or delaying brain developmental processes ([@B166]; [@B69]). A reduction in the normal fetal neurosteroid environment is thus associated with adverse outcomes, such as the occurrence of potentially damaging seizures which can lead to destructive and permanent alterations in neurodevelopment ([@B167]). Following preterm birth there is a premature reduction in the supply of neurosteroids, including progesterone and its neuroactive metabolite allopregnanolone, resulting in an already vulnerable premature neonate being exposed to the *ex utero* environment without neuroprotection.

![Neurosteroidogenesis in the placenta and fetal brain. Cholesterol is metabolized into progesterone by the enzymes cholesterol side-chain cleavage (P450scc) and 3β-hydroxysteroid dehydrogenase (3β-HSD). The rate-limiting enzymes 5α-reductase type 1 and 2 (5α-R) facilitate the conversion of progesterone into 5α-dihydroprogesterone (5α-DHP). Allopregnanolone is then synthesized from this precursor by 3α-hydroxysteroid dehydrogenase (3α-HSD). This process can occur both within the placenta, and *de novo* within the fetal brain.](fphys-10-00599-g001){#F1}

Importance of the Fetal Neurosteroid Allopregnanolone for Brain Development
---------------------------------------------------------------------------

Reductions in white matter is suggested to be a key component in the development of neurobehavioral disorders in children that are born preterm ([@B121]) and may stem from the birth-associated loss of allopregnanolone, as the pro-myelinating effects of this neurosteroid are evident *in vitro* on rat cerebellar slice cultures ([@B45]). Allopregnanolone induced protection against cell death has been demonstrated in an *in vivo* mouse model of neurodegeneration ([@B79]) and in a sheep model of acute fetal hypoxia which is also important in maintaining levels of mature myelination oligodendrocytes ([@B166]). Allopregnanolone is metabolized by the rate limiting enzymes 5α-reductases type 1 and 2 (5αR1 and 2) from progesterone ([Figure 1](#F1){ref-type="fig"}) ([@B90]; [@B95]). In addition to the allopregnanolone supplied by the placenta to the fetus, the fetal brain is also capable of metabolizing allopregnanolone from placentally derived precursors including progesterone and 5α-dihyroprogesterone (5α-pregnane-3,20-dione), thus there is also a high level of allopregnanolone locally produced and maintained within the fetal brain ([@B143]; [@B104]). However, we have previously shown in the developmentally relevant guinea pig ([@B100]), a precocial species with similar hormonal profile to humans throughout pregnancy, that following the loss of the placenta at birth both progesterone and allopregnanolone levels decline rapidly within 24 h, highlighting the necessity of the placenta for the supply of steroidogenic precursors ([@B67]). Both of the rate-limiting enzymes 5αR1 and 2 are expressed in the placenta, and sheep and rat studies show that the 5αR2 isoform is most strongly expressed on neurons and glia within the developing fetal brain in late gestation ([@B90]; [@B103]).

Birth-associated loss of gestational allopregnanolone concentrations occurs earlier than normal in neonates that are born preterm leading to a damaging increase in excitation. Recent studies by our group have shown there is a dramatic drop in brain allopregnanolone concentrations following term and preterm birth compared to fetal levels ([@B68], [@B67]). Furthermore, preterm delivered animals also had significantly decreased myelination (evidenced by reduced MBP expression) in the CA1 region of the hippocampus and adjacent subcortical white matter 24 h after delivery compared to animals delivered at term ([@B67]). We have also shown that preterm male and female neonates at term equivalence age exhibit deficits in MBP immunostaining of the CA1 region, subcortical white matter and posterior lobe of the cerebellum ([@B67]; [@B111]), and that juvenile offspring present with lasting deficits in myelination of these regions in male and female guinea pigs ([@B134], [@B133]). Likewise, reduced allopregnanolone supply as a result of intrauterine growth restriction and also impairs myelin development of the CA1 in male fetuses ([@B32]). We have found that the late developing cerebellum is particularly vulnerable to the insults associated with preterm delivery. In addition to the CA1 region of the hippocampus, reductions in myelination of the posterior lobe of the cerebellum were evident in preterm guinea pig neonates at PND1 ([@B135]). Furthermore, at term equivalence age we have demonstrated that not only is the expression of the level of mature oligodendrocytes reduced, but also that reductions are present throughout the oligodendrocyte lineage thereby lessening the potential of catch-up growth to occur ([@B111]). By juvenile age we further observed that there were sex dependent alterations in myelination of the posterior lobe of the cerebellum as well as in components of the GABAergic pathway ([@B133]). Functional imaging studies suggest that the posterior lobe of the cerebellum is particularly involved in cognition and emotion ([@B144]), as it is interconnected with the prefrontal cortex, association cortices, and the limbic system, which allows for its involvement in higher order executive functioning ([@B145]). Therefore, the altered development of this area may be having a role in some of the neurobehavioral disorders that are more common following premature birth, such as ADHD and autism.

Our studies indicate that juvenile males show a hyperactive phenotype following preterm birth ([@B134]). Additionally, they exhibit behavior similar to that observed in mouse models of ADHD where, as with our study, within open field test conditions the spontaneous distance traveled, and time spent mobile is markedly higher for the affected mice compared to the controls ([@B70]). This hyperactive behavior has parallels with clinical studies where ex-preterm male children show an increased incidence of hyperactivity disorders ([@B82]; [@B81]). Taken together, these data emphasize the importance of allopregnanolone for myelination and optimal development of the GABAergic system to occur in fetal and neonatal life. We therefore speculate that the changes in neurodevelopmental and behavioral function we see following preterm birth may be accounted for by the loss of allopregnanolone supply.

Pharmacological Reduction of the *in utero* Neurosteroid Environment
--------------------------------------------------------------------

The deficits in myelination seen following preterm birth can be mimicked by the administration of a 5α-reductase inhibitor, finasteride, directly to the fetal circulation preventing the metabolism of progesterone to allopregnanolone within the fetal brain. This intervention results in an increase of damaging excitation in the brain of fetal sheep due to reduced suppression by allopregnanolone ([@B107]). As a result of this excitation, cell death is increased in areas such as the hippocampus, cerebellum, and white matter tracts. In another study in fetal sheep, allopregnanolone synthesis was reduced through inhibition of progesterone production by trilostane (a 3β-hydroxysteroid dehydrogenase inhibitor). This resulted in reduced fetal sleep-like behavior but increased arousal-like activity ([@B28]), resulting in increased brain excitability and damaging seizures ([@B97]; [@B106]). Furthermore, when progesterone was replaced by exogenous supplementation, the occurrence of sleep-like behavior returned to normal fetal patterns ([@B28]). Exposure to finasteride has also been shown to increase apoptotic cells in the CA1 and CA3 regions of the hippocampus, and the cerebellar molecular and granular layers in fetal sheep, as well as increasing the number of dead Purkinje cells in the cerebellum ([@B164]). Importantly, co-infusion of finasteride and the allopregnanolone analog alfaxolone completely ameliorated the deleterious effects of finasteride treatment. Similarly allopregnanolone itself has also been shown to protect the fetal brain when insults occur, in a sheep model the introduction of brief asphyxia in the presence of finasteride induced cell death in the hippocampus, however, when allopregnanolone was present in normal concentrations this asphyxia- induced damage did not occur ([@B107]). *In utero* administration of finasteride to guinea pigs has also highlighted the key role of allopregnanolone in myelination, as a reduction in myelination in the subcortical white matter was present following inhibition of allopregnanolone synthesis ([@B69]). Interestingly, administration of the allopregnanolone precursor, progesterone, to *in vitro* rat cerebellum slices increased both the proliferation of myelinating oligodendrocytes and the rate of myelination ([@B45]). Follow up studies then revealed that this effect was achieved by neurosteroids acting on the GABA~A~ receptors ([@B44]). Together these studies emphasize the important role of allopregnanolone in not just the development of the brain, but also for protection from hypoxia ([Figure 2](#F2){ref-type="fig"}).

![Proposed cascade of events following preterm birth that lead to ongoing neurological impairments.](fphys-10-00599-g002){#F2}

A reduction in allopregnanolone concentrations during pregnancy can also have long-lasting effects on the offspring. In guinea pigs, late gestation maternally administered finasteride resulted in an anxiety-like phenotype in female offspring, along with reductions in components of the GABAergic pathway within the amygdala ([@B31]). Furthermore, there was also decreased expression of neurosteroid-sensitive GABA~A~ receptors and increased astrocyte activation within the cerebellum of these animals ([@B33]). In a similar study, finasteride treatment to pregnant rats during late gestation resulted in increased serum corticosterone concentrations in their juvenile offspring, decreased hippocampal allopregnanolone levels and impaired performance in memory tasks ([@B112]). Studies inhibiting the production of allopregnanolone in adult rats highlight the importance of allopregnanolone for the prevention of neurodevelopmental disorders throughout life as reductions in the concentration of allopregnanolone within the hippocampus ([@B42]) or the amygdala ([@B158]) increased anxiety-like behaviors in these animals. Furthermore, multiple neurological conditions are characterized by a reduced level of circulating allopregnanolone in adults, including post-traumatic stress disorder ([@B118]), major depressive disorder ([@B146]), and premenstrual dysphoric disorder ([@B99]; [@B84]).

Combined Effect of Reduced Neurosteroid Exposure and Increased Cortisol
-----------------------------------------------------------------------

An underlying factor involved in the development of hyperactivity and anxiety following preterm birth may be increased cortisol. In our studies we have observed increased circulating cortisol levels in preterm offspring at birth ([@B135]), PND1 ([@B135]), and juvenility ([@B134]). In humans, one study has found that as birth weight and gestational age decreases, there is an increase in circulating cortisol ([@B61]), and early life stress has also been shown to negatively impact hippocampal development with long-term effects into adolescence ([@B57]). Interestingly at juvenility, we found that male preterm offspring had increased baseline concentrations of circulating cortisol that were unaffected by exposure to foreign situations (in the form of behavioral testing). Meanwhile, juvenile females born preterm experienced a substantial rise in cortisol in response to foreign situations compared to term-born females, suggesting that they have an anxious phenotype and increased fear response ([@B134]). These data highlight the sexually dimorphic effects that preterm birth has on programming of the hypothalamic pituitary axis, with a blunting of the stress response following preterm birth in males, but an increased response in females. Previous studies in guinea pigs suggest that prenatally increased cortisol may program adverse behavior in childhood, for example maternal stress exposure in pregnancy was shown to result in increased anxious behaviors in juvenile female offspring ([@B11]). This is consistent with studies showing that prenatal stresses 'programs' the HPA axis ([@B64], [@B65]; [@B63]). This results in a greater postnatal sensitivity of the HPA axis to stressful stimuli, in turn contributing to behavioral disorders. The programming mechanism has been shown to be mediated by changes at the level of the hypothalamus ([@B64], [@B65]; [@B63]). Therefore, even in the absence of a parallel change in postnatal cortisol concentrations, early exposure to increased cortisol concentration can program an altered behavioral response to stress-inducing situations.

These behavior-altering effects of cortisol may also involve interactions between cortisol and allopregnanolone. Glucocorticoids, such as cortisol, are known to adversely affect allopregnanolone production. Studies in guinea pigs have previously demonstrated that repeated administration of betamethasone (a synthetic glucocorticoid) to pregnant dams reduced the allopregnanolone synthesizing capacity of both the placenta and the fetal brain as demonstrated by a reduction in the expression of the rate-limiting enzyme 5α-reductase type 2 in both tissues ([@B93]). Interestingly expression of this enzyme is also decreased in the brain of preterm guinea pig neonates ([@B67]), possibly as a result of exogenous glucocorticoid exposure, part of the gold standard treatment to reduce short-term morbidity and mortality following preterm birth. Our studies have also shown that both late gestation maternal stress and pharmacological inhibition of allopregnanolone synthesis by finasteride result in a reduction of allopregnanolone concentrations in the fetus, with development of an anxious phenotype in female juvenile offspring ([@B11]; [@B31]). In light of these data and the findings of the studies presented here we suggest that in addition to the lack of protection of allopregnanolone against excitotoxic damage, and the raised levels of cortisol present following early exposure to the *ex utero* environment, that cortisol hinders the synthesis and action of any offspring derived allopregnanolone in the preterm neonate and that this has lasting implications on neurodevelopment and behavior ([Figure 2](#F2){ref-type="fig"}).

Neurosteroids and the Extra Synaptic Gaba~A~ Receptor
=====================================================

Inhibitory allopregnanolone exert effects throughout the brain to suppress excessive excitation. This suppression is achieved by increasing GABAergic inhibition ([@B54]). Allopregnanolone is an allosteric agonist of the GABA~A~ receptors and specifically enhances GABA~A~ receptor mediated inhibition, which results in anxiolytic, anti-convulsant, anesthetic, analgesic, and sedative effects ([@B51]; [@B50]; [@B73]; [@B88]; [@B113]; [@B109]; [@B10]). These effects are achieved by activation of the extra synaptic receptors, which are known to be particularly sensitive to allopregnanolone. GABA~A~ receptors form a gated chloride ionophore channel and specific binding sites for benzodiazepines, barbiturates, and anesthetics, however, neurosteroids are thought to bind to a separate allosteric steroid-binding site ([@B35]; [@B87]). GABA~A~ receptors exhibit inhibitory effects in response to neurosteroid stimulation in adult animals and from mid gestation onward in the fetus, however, they are also capable of exhibiting excitatory actions in early gestation and these excitatory actions are known to stimulate glial cells and neuronal outgrowth ([@B110]; [@B122]). Whether the effect is inhibitory or excitatory is determined by the chloride gradient of the receptor-ionophore, determined by the intracellular chloride concentration. This in turn is primarily regulated by the K^+^/Cl^--^ co-transporter-2 (KCC2) ([@B124], [@B123]). The expression and activity of this integral co-transporter is regulated by the phosphorylation of its Ser940 residue, with dephosphorylation resulting in downregulation of the co-transporter, increasing the intracellular chloride concentration, and switching to excitatory GABA actions ([@B77]; [@B76]).

GABA~A~ receptors are involved in a broad range of functions including controlling the excitability of the brain, modulation of anxiety, as well as cognition, memory, and learning ([@B136]). In addition to neurons, extra synaptic neurosteroid sensitive receptors are highly expressed on glial cells including oligodendrocytes ([@B3]) throughout the fetal brain from mid-gestation onward ([@B160]; [@B30]; [@B56]). The expression of GABA~A~ receptors in the fetal brain increases as gestation advances, reaching their highest levels of expression by full term gestation in most areas, such as the cerebral cortex and hypothalamus ([@B30], [@B29]; [@B103]). GABA~A~ receptors exist in a pentameric formation of 5 subunits with a central selective chloride anion channel. The five subunits come from a pool of 19 different subunits, α1-6, β1-3, γ1-3, δ, ε, π, θ, and ρ1-3 and subunit composition varies greatly depending on the function of the receptor ([@B6]; [@B9]). Synaptic receptors, which are responsible for fast transmission, usually feature the α1-3, β1-3, and γ2 subunits ([@B40]), whilst the extra synaptic receptors that contribute to tonic inhibition ([@B9]) possess the α4-6 and δ subunits ([@B14]). Rather than produce an increase in amplitude of miniature inhibitory postsynaptic currents (mIPSCs), neurosteroids have been shown to increase the duration of the amplification by altering the kinetics of the GABA~A~-gated ion channels ([@B74]). This increase in duration is neuron specific, with different brain regions requiring different concentrations of neurosteroids to induce the same effect. Specifically, the CA1 neurons of the hippocampus, cerebellar granule cells, and Purkinje cells appear to be more sensitive to neurosteroids, only requiring low nanomolar concentrations to increase duration of amplification ([@B49]; [@B25]), and this is primarily due to subunit composition.

Receptor subunit composition plays an important role in determining receptor affinity for various ligands. Benzodiazepines for example are known to be attracted to receptors containing a γ subunit, whilst those featuring α6 are unresponsive to benzodiazepines ([@B35]). Whilst there is a specific binding site for 3α-hydroxy-neurosteroids such as allopregnanolone, the composition of subunits affects the sensitivity of the receptor to stimulation ([@B8]; [@B58]). Regional specificity also exists for these receptors, for example in a mouse knockout of the δ subunit tonic conductance was significantly reduced in the cerebellum, however, in the CA1 region of the hippocampus there was no effect on conductance ([@B142]). This regional specificity is due to differences in expression of various subunits throughout the brain and whilst the α6 and δ subunits, which are co-expressed in many receptors, are highly expressed in the cerebellum, tonic conductance in the hippocampus is controlled primarily by receptors containing the α4 and α5 subunits, in addition to those containing the δ subunit.

The role of specific neurosteroid-sensitive subunits in behavior has been revealed in knockout mouse models. For example, global deletion of the δ subunit significantly reduces the anxiolytic and anti-convulsant effects induced by the allopregnanolone analog ganaxolone, confirming that neurosteroids bind to the δ subunit containing GABA~A~ receptors to exert their inhibitory functions ([@B96]). Increased anxiety-like behavior was also present in a α4 subunit knockout mice as demonstrated by an increased preference for dark enclosed spaces in a T-maze ([@B85]). Seizure susceptibility has also been shown as increased following this knockout ([@B17]). Similarly, it has been demonstrated that pro-epileptic behavior is increased in mice lacking the δ subunit ([@B96]; [@B140], [@B141]). Taken together these data indicate the importance of configurations of the GABA~A~ receptors and the necessity of the expression of key subunits for neurosteroid binding and for their effects on behavior.

Of particular importance to preterm-associated neurodevelopmental impairment is the ability of allopregnanolone to promote GABA~A~ receptor-mediated maturation of oligodendrocytes. Administration of progesterone to rat cerebellar slice cultures increased the expression of the mature myelinating oligodendrocyte marker, myelin basic protein (MBP) ([@B45]). The enhancement of myelination was achieved by allopregnanolone, the neuroactive metabolite of progesterone, acting via the GABA~A~ receptors located on oligodendrocytes as a selective GABA~A~ receptor antagonist inhibited this promyelinating effect.

GABA~A~ Receptors and Preterm Birth
===================================

In juvenile guinea pigs born preterm, altered GABAergic pathway development is evident at juvenility in the cerebellum. Intriguingly, despite reduced expression of both subunits in the preterm neonatal cerebellums ([Figure 3](#F3){ref-type="fig"}) ([@B135]) mRNA expression of allopregnanolone sensitive GABA~A~ receptor subunits α6 and δ are not altered in these preterm-born animals at juvenility ([@B133]). These observations suggest that sometime between birth and juvenile age in the guinea pig (PND28) there is either a 'catch-up' in these key GABA~A~ receptor subunits expression, or conversely, that levels in the brain of term born animals have dropped to lower levels. Subunits of the GABA~A~ receptor are reported to go through age-related changes in expression, with early development often a period of high expression, followed by down regulation in adulthood ([@B168]). This age-related change in expression follows the maturation profile of the brain and therefore if the neurosteroid-sensitive receptors in the preterm brain do not undergo any 'catch-up' between birth and juvenility this may contribute to preterm-associated changes in neurodevelopment. An additional vulnerability that has been reported for preterm neonates is an observed lack of a birth-related adaptive increase in the cerebellar expression of the α6 and δ GABA~A~ receptor subunits after birth ([Figure 2](#F2){ref-type="fig"}) ([@B135]). This potentially reduces the effect of allopregnanolone postnatally, exposing the immature brain to damaging excitotoxicity. Knockout studies of the δ subunit, which is known to commonly group with the α6 subunit, have shown a link between a lack of these subunits with the manifestation of multiple neurodevelopmental phenotypes such as anxiety-like behavior and pro-epileptic behavior ([@B96]; [@B140], [@B141]). Interestingly, receptor changes are present in human brain tissue in disorders that primarily affect myelination, such as multiple sclerosis ([@B86]), and whilst their precise role in disease progression is unknown, the neurosteroid sensitive GABA~A~ receptors present a common link between initial myelination, 'catch up' and remyelination processes, and behavioral state.

![Relative mRNA expression of the GABA~A~ receptor **(A)** δ and **(B)** α6 subunits in guinea pig cerebellum. Fetal tissue was obtained at GA69 (term) and GA62 (preterm) ages, and neonatal tissue from 24 h after term or preterm birth. (\**p* \< 0.05, *n* = 11--16). Adapted and reprinted with permission from [@B135].](fphys-10-00599-g003){#F3}

Conversely, the hippocampal GABA~A~ neurosteroid sensitive receptor subunits appear to be largely unaffected by preterm delivery with the exception of a decrease in the expression of the α5 subunit mRNA at juvenility ([@B134]). This particular subunit is known to mediate tonic inhibition in the CA1 of the hippocampus, is required for associative learning and furthermore is known to be reduced in response to increased levels of cortisol ([@B27]; [@B150]; [@B46]). Thus, a reduction in α5 subunit expression in childhood may reduce tonic inhibition, thereby increasing excitation in the hippocampus, which in turn may contribute to the risk of hyperactivity-disorders in male children born preterm.

Potential of Neurosteroids as a Protective Therapy
==================================================

Steroid hormones, including progesterone, allopregnanolone and potentially other neuroactive metabolites, can exert neuroprotective effects following damage to neurons and glia by preventing excitation, apoptosis, and inflammation, as well as by regenerative mechanisms ([@B131]). Studies in adult rats have demonstrated the therapeutic effect of progesterone injections on TBI where progesterone administration reduced neuronal loss ([@B127], [@B128]; [@B53]). Similarly, allopregnanolone administration was shown to reduce memory deficits and loss of neurons in the frontal cortex of these rats following bilateral injury by stimulating trophic effects ([@B53]). Importantly, in rat astrocytes and oligodendroglial progenitor primary cell cultures, progesterone exposure upregulated expression of the promyelinating factor insulin-like growth factor 1 ([@B20]) and, in organotypic slice cultures of rat cerebellum, myelination was stimulated by progesterone following its metabolism into allopregnanolone and its' trophic actions mediated by actions on GABA~A~ receptors ([@B45]). Both progesterone and allopregnanolone have been shown to be effective at reducing the pro-apoptotic activity of caspase-3, reducing astrogliosis as evidenced by GFAP staining, and improving performance in both the spatial learning task and memory function in adult male rats ([@B36]). Furthermore, rat studies have identified reductions in inflammatory cytokines TNF-α and IL-1β following TBI and subsequent progesterone or allopregnanolone administration ([@B52]). Following the potential benefits of progesterone therapy observed in animal studies, a randomized phase III clinical trial of progesterone (ProTECT) for treatment of acute TBI in adults was performed. This showed that progesterone treatment resulted in a lower 30-day mortality risk, and that patients were more likely to have a moderate to good outcome than those receiving placebo ([@B162]). Likewise, a large clinical trial in China is showing similar therapeutic benefits following progesterone therapy ([@B163]).

The role of progesterone as a precursor of allopregnanolone, and the number of positive studies relating to the use of progesterone, led to us examining the use of progesterone replacement therapy in preterm guinea pig neonates. In contrast to the earlier finding of effects on TBI in rats, we observed detrimental effects on postnatal neurodevelopment particularly in the male offspring. From this preliminary study, it appears that progesterone is metabolized differently by the male neonates and instead of producing allopregnanolone, much of the steroid is converted to cortisol. These males, with high plasma and salivary cortisol concentrations, also had reductions in myelination of the cerebellum and subcortical white matter, highlighting the vulnerability of these male neonates to increased cortisol as a result of increased postnatal progesterone ([@B111]).

Previous studies have also investigated the potential use of allopregnanolone to restore neurosteroid deficits. Preliminary findings, however, suggested that allopregnanolone had limited effectiveness due to the very short half-life of allopregnanolone, or other possible metabolic conversion making therapeutic concentration difficult to achieve. To avoid both of these issues with allopregnanolone therapy, as well as potential conversion of allopregnanolone to its less active isomers, we explored a possible postnatal therapy with ganaxolone.

Ganaxolone
----------

Ganaxolone is a 3β-methylated synthetic analog of allopregnanolone initially developed by Edward Monaghan at CoSensys in 1998, however, in 2004 Marinus Pharmaceuticals Inc., acquired the development and commercialization rights ([@B108]). Marinus Pharmaceuticals then carried out a number of clinical trials using ganaxolone, some of which are still ongoing. Ganaxolone features a methyl group that prevents metabolism into other active steroids ([@B16]), and a half-life of 12--20 h in humans ([@B98]). Ganaxolone acts in a very similar manner to allopregnanolone and binds to the neurosteroid-binding site of GABA~A~ receptors, producing similar anxiolytic and anti-seizure effects. The addition of the methyl group markedly improves oral pharmacokinetics and in addition ganaxolone is not readily metabolized to other steroids that may bind elsewhere and produce unwanted effects ([@B16]). Allopregnanolone can for example be metabolized into the 3β-isomer that is either inactive, or at higher doses, may block the steroid site on the GABA~A~ receptor.

Animal pharmacokinetic studies demonstrate that ganaxolone has a large volume of distribution as administration of radioactively labeled ganaxolone has shown wide distribution, and due to its' lipophilic nature, it becomes concentrated in the brain with a brain-to-plasma concentration of between 5 and 10 ([@B108]; [@B119]). In addition to pharmacokinetic studies there have been a number of animal studies relating to the use of ganaxolone and behavioral disorders. In an adult mouse model of Angelman syndrome (which is characterized by severe developmental delay, motor impairments, and epilepsy) treatment with ganaxolone over a period of 4 weeks was shown to ameliorate behavioral abnormalities ([@B22]). Other mouse models of neurodevelopmental disorders have highlighted the therapeutic benefits of ganaxolone, including an adult mouse model of autism where ganaxolone reversed the autistic phenotype ([@B66]), and an adult post-traumatic stress mouse model where again ganaxolone therapy improved behavioral changes such as aggression and anxiety ([@B115]). Despite numerous animal models of behavioral disorders demonstrating the therapeutic potential of ganaxolone in ameliorating disease states, there is limited information regarding the effects on neurodevelopment or myelination in these models. There has been one model where administration of ganaxolone to Niemann-Pick Type C diseased adult mice identified protection against Purkinje cell death, which is similar to the previously reported protective mechanisms of allopregnanolone ([@B94]). Furthermore, there has only been one neonatal animal study using ganaxolone therapy, in a rat model of infantile spasms where the onset, number, and duration of spasms were reduced by ganaxolone therapy ([@B169]). An additional study examining the neuroprotective effects of ganaxolone following neonatal seizures in sheep is ongoing but shows promise ([@B165]).

A number of phase 2 clinical trials have examined the use of ganaxolone for epilepsy and infantile spasms, as well as for posttraumatic stress disorder, migraine, and the developmental problems associated with fragile X syndrome ([@B108]; [@B119]). Daily drug doses of up to 1,875 mg in adults and 54 mg/kg in children have been trialed, and it has been shown that a single oral dose of 1,600 mg can result in peak plasma concentrations of up to 460 ng/mL. Recently a randomized phase 2 trial for ganaxolone as an add-on therapy for severe seizure disorders took place in 147 adults ([@B139]). The subjects received 1,500 mg/day spread over three doses for 8 weeks. The treatment resulted in an 18% decrease in mean weekly seizure frequency, compared to a 2% increase in the placebo group. The treatment was reported as safe and well tolerated with similar rates of discontinuation due to adverse effects in the placebo and ganaxolone groups (ganaxolone 7.1% versus 6.1% for placebo). The most common side effects were classified as mild to moderate and included dizziness (16.3% versus 8.2% in placebo), fatigue (16.3% versus 8.2%), and somnolence (13.3% versus 2.0%).

In the context of preterm birth, we have recently reported that ganaxolone neurosteroid-replacement therapy given to preterm guinea pigs between birth and term 'due date' improved myelination of the CA1 region of the hippocampus and overlying subcortical white matter, in addition to reduction in hyperactive behavior ([@B132]). This was the first study to show that neurosteroid-replacement therapy can replicate the *in utero* neurosteroid environment and that this restores neurodevelopment to a normal, term-born, trajectory ([Figure 4](#F4){ref-type="fig"}). By combining our recent studies on pregnancy compromises in the developmentally relevant guinea pig ([@B100]) and the impact of disturbances in allopregnanolone levels on the developing fetus, the preterm neonate, and the long-term effects on the juvenile, we now suggest that re-establishment of neurosteroid action in the period between birth and term equivalence is a prospective therapy for future clinical use. Whilst more studies required, particularly on optimal dosing and longer-term outcomes, we suggest this study provides the impetus and a path for future preclinical trials using neurosteroid-replacement therapy following preterm birth. Furthermore, this therapy may be useful following other pregnancy compromises discussed previously where a major contributing factor to deficits in neurodevelopment is a lack of allopregnanolone exposure.

![Myelination, the process of surrounding nerve axons with a myelin sheath, is achieved by oligodendrocytes. Placentally derived allopregnanolone (ALLO), the neuroactive metabolite of progesterone (PROG), promotes maturation of oligodendrocytes *in utero* via action on GABA~A~ receptors in **(A)**; premature loss of the placenta due to preterm birth results in an arrest in this process in **(B)**; and reinstating GABA~A~ receptor signaling by neurosteroid-replacement therapy may restore oligodendrocyte maturation leading to correct myelination in neonates born preterm, thus improving neurological function in **(C)**.](fphys-10-00599-g004){#F4}

Conclusion
==========

Until recently, the risk of neurodevelopmental impairment in children born moderate-late preterm who required little to no clinical intervention, was thought to be minimal, however, data from large international cohorts clearly demonstrate that this is not the case. Albeit that the effect size is not as great as for those born at extremes of gestational age, the significantly larger number of children born at moderate-late preterm gestations means that this is an increasingly large public health issue, with important implications for the provision of educational and other resources throughout childhood. Currently, there are no targeted therapies available to prevent the development of these neurodevelopmental problems, and as such therapy is limited to symptom management for the most affected children.

Through use of studies in our model of preterm birth in the guinea pig we have begun to address these gaps in the knowledge of neurodevelopment following preterm birth. We suggest key pathways involved, targets for intervention, and a therapy for prevention of preterm-associated neurodevelopmental disorders. These studies are in their preliminary stages and whilst we have identified a target for improving outcomes, there are many aspects to this therapy that we are yet to investigate. Our pilot studies are primarily focused on identifying an optimal dose that promotes oligodendrocyte maturation but minimizes adverse side effects. Once we identify an ideal dose, we can then determine whether there are interactions with other therapies that the preterm neonate may be exposed to, such as synthetic glucocorticoids, and potentially in the future, for asphyxiated preterm infants, therapeutic hypothermia as a co-therapy.
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